Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 679 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... May 17, 2023 Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... May 31, 2024 Many Older Adults Screened Unnecessarily for Common Cancers August 27, 2020 Exosomes May Help Tumors Evade Immune System September 7, 2018 Load more HOT NEWS It’s a fair COP: Why our chief clinician went to a... 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
